Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FEHMIDA ZAHABI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1740397603
CMS profile
305709
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$9,213.79

255 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,080.41 251
Consulting Fee $3,294.00 2
Honoraria $1,800.00 1
Education $39.38 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FEHMIDA ZAHABI

NPI 1740397603 · CMS profile ID 305709

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

255 matching records · $9,213.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 255 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–255 of 255.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Radius Health, Inc. $18.7201/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830729349 CMS
AbbVie Inc. $3.9101/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796298219 CMS
E.R. Squibb & Sons, L.L.C. $23.6801/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783402209 CMS
Lilly USA, LLC $11.0801/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819085157 CMS
Lilly USA, LLC $1.5001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819145517 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,427.54 253
PY2020 $5,777.04 210
PY2021 $9,213.79 255
PY2022 $4,931.68 225
PY2023 $2,927.10 172
PY2024 $3,488.85 175
PY2025 $3,706.16 166

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $263,516.83 63
PY2024 Recipient $104.58 1
PY2024 Principal investigator $416,620.60 69
PY2023 Recipient $1,098.96 7
PY2023 Principal investigator $436,116.90 71
PY2022 Principal investigator $373,537.01 72
PY2021 Principal investigator $278,146.55 75
PY2020 Principal investigator $329,485.34 98
PY2019 Recipient $254.48 5
PY2019 Principal investigator $378,141.40 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $134.66 12/31/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIATES INC
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202533211
Principal investigator 1 Janssen Research & Development, LLC $5,113.00 12/22/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369379
Principal investigator 1 ABBVIE INC. $2,863.45 12/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527810
Principal investigator 1 ABBVIE INC. $2,918.85 12/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202527812
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $187.19 12/03/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289164
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53.78 12/03/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289166
Principal investigator 1 ABBVIE INC. $3,000.00 11/26/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525688
Principal investigator 1 ABBVIE INC. $4,410.00 11/26/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525690
Principal investigator 1 ABBVIE INC. $1,509.30 11/25/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525318
Principal investigator 1 ABBVIE INC. $893.63 11/25/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525328
Principal investigator 1 ABBVIE INC. $300.00 11/25/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525330
Principal investigator 1 ABBVIE INC. $1,000.00 11/20/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524876
Principal investigator 1 ABBVIE INC. $900.00 11/20/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524884
Principal investigator 1 ABBVIE INC. $2,916.00 11/20/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525010
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18.55 11/20/2025 Non-covered Recipient Entity
Trinity Universal Research Associates
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235992869
Principal investigator 1 ABBVIE INC. $5,018.25 11/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520595
Principal investigator 1 ABBVIE INC. $12,971.20 11/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520637
Principal investigator 1 ABBVIE INC. $6,385.05 11/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521109
Principal investigator 1 ABBVIE INC. $3,834.00 10/16/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517207
Principal investigator 1 ABBVIE INC. $625.00 10/16/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,673.20 10/15/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286941
Principal investigator 1 ABBVIE INC. $3,312.00 10/14/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516661
Principal investigator 1 ABBVIE INC. $3,228.00 10/09/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202514857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,388.00 10/03/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286299
Principal investigator 1 Janssen Research & Development, LLC $1,932.00 09/29/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369407
Principal investigator 1 ABBVIE INC. $5,401.05 09/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,799.73 09/03/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 08/20/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 08/20/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284423
Principal investigator 1 Janssen Research & Development, LLC $4,450.00 08/11/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369399
Principal investigator 1 ABBVIE INC. $4,324.00 08/05/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202502016
Principal investigator 1 Janssen Research & Development, LLC $976.00 07/07/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369387
Principal investigator 1 ABBVIE INC. $11,020.35 07/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202495521
Principal investigator 1 ABBVIE INC. $2,928.25 07/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495523
Principal investigator 1 ABBVIE INC. $7,341.30 07/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202495525
Principal investigator 1 ABBVIE INC. $3,607.35 06/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202489013
Principal investigator 1 ABBVIE INC. $464.30 06/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202489015
Principal investigator 1 ABBVIE INC. $2,278.80 06/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202489017
Principal investigator 1 Janssen Research & Development, LLC $2,928.00 06/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,933.00 05/21/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279992
Principal investigator 1 ABBVIE INC. $1,882.45 05/06/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481739
Principal investigator 1 ABBVIE INC. $6,420.80 05/06/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481795
Principal investigator 1 Janssen Research & Development, LLC $3,823.00 04/28/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369362
Principal investigator 1 Eli Lilly and Company $20,700.00 04/22/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIATES INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187891492
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,933.00 04/18/2025 Non-covered Recipient Entity
CLINITIATIVE HEALTH RESEARCH
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278476
Principal investigator 1 GlaxoSmithKline, LLC. $1,057.00 04/04/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIATES INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192175075
Principal investigator 1 ABBVIE INC. $3,526.80 04/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202469307
Principal investigator 1 ABBVIE INC. $3,403.45 04/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202469482
Principal investigator 1 ABBVIE INC. $4,256.70 04/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202469487
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 04/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIATES INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192175071
Principal investigator 1 Janssen Research & Development, LLC $3,912.00 03/31/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369371
Principal investigator 1 ABBVIE INC. $5,734.20 03/06/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202458601
Principal investigator 1 ABBVIE INC. $10,619.30 03/06/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202458720
Principal investigator 1 ABBVIE INC. $6,067.05 03/06/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458913
Principal investigator 1 Janssen Research & Development, LLC $4,128.00 03/03/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369414
Principal investigator 1 ABBVIE INC. $4,713.00 02/05/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444842
Principal investigator 1 ABBVIE INC. $3,065.80 02/05/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444872
Principal investigator 1 ABBVIE INC. $4,569.90 02/05/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202446531
Principal investigator 1 Janssen Research & Development, LLC $5,061.00 01/27/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175369394
Principal investigator 1 SANOFI US SERVICES INC. $3,800.00 01/27/2025 Non-covered Recipient Entity
Trinity Universal Research Associat
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226146304
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,529.59 01/21/2025 Non-covered Recipient Entity
Trinity Universal Research Associates
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235992867
Principal investigator 1 ABBVIE INC. $2,000.00 01/16/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202439302
Principal investigator 1 ABBVIE INC. $3,776.55 01/02/2025 Non-covered Recipient Entity
TRINITY UNIVERSAL RESEARCH ASSOCIAT
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202436038